Statin (Cerivastatin) Protects Mice Against Sepsis-Related Death via Reduced Proinflammatory Cytokines and Enhanced Bacterial Clearance
Authors:
- 1 April 2008
- journal article
- Published by SAGE Publications in Surgical Infections
- Vol. 9 (2) , 183-194
Abstract
Death attributable to septic shock syndrome depends highly on the inflammatory response and cytokine production. Inhibition of inflammation is one of the many pleiotropic effects of statins. The aim of this study was to test the hypothesis that statins have a role in altering the host response to bacterial infections and thus would prove beneficial in the prevention of microbial sepsis. Male C57BL/6 and C3H/HeN mice received cerivastatin (4 mg/kg) or phosphate-buffered saline (PBS) intraperitoneally (i.p.), 24 and 1 h before and 24, 48, and 72 h after bacterial challenges. Sepsis was induced by i.p. injection of lipopolysaccharide (LPS) (45 mg/kg), Staphylococcus aureus (5 x 10(7) colony-forming units [CFU]/mouse), or Salmonella typhimurium (2.5 x 10(6) CFU/mouse). Administration of cerivastatin improved significantly the survival rate of mice challenged with LPS (31% vs. 19% in the PBS group; p = 0.001), S. aureus (56% vs. 20% in PBS group; p = 0.01), or S. typhimurium (48% vs. 10% in PBS group; p = 0.03). Significantly reduced release of the pro-inflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 was evident in cerivastatin-treated mice after LPS challenge. Cerivastatin-treated mice showed insignificant reductions in serum TNF-alpha and IL-6 concentrations after bacterial challenge. However, significantly accelerated bacterial clearance was demonstrated in cerivastatin-treated mice 24 h after S. typhimurium infection and 48 h after S. aureus infection. Cerivastatin protects mice against LPS- and live bacteria-induced death, an effect associated with cerivastatin-attenuated pro-inflammatory cytokine production and enhanced bacterial clearance. Hence, application of statins in the clinical setting may prove beneficial in prevention of LPS or bacterial infection-related sepsis.Keywords
This publication has 39 references indexed in Scilit:
- Simvastatin Blunts Endotoxin-Induced Tissue Factor In VivoCirculation, 2005
- HMG-CoA reductase inhibitors induce COX-2 gene expression in murine macrophages: role of MAPK cascades and promoter elements for CREB and C/EBPβExperimental Cell Research, 2004
- HMG-CoA Reductase Inhibitor Simvastatin Profoundly Improves Survival in a Murine Model of SepsisCirculation, 2004
- New concepts in sepsisCurrent Opinion in Critical Care, 2002
- The Effect of Statins on Mortality in Patients with BacteremiaClinical Infectious Diseases, 2001
- Anti-inflammatory therapies in sepsis and septic shockExpert Opinion on Investigational Drugs, 2000
- Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.Journal of Clinical Investigation, 1998
- Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway productsAtherosclerosis, 1991
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Inhibition of Cholesterol Synthesis in vitro and in vivo by ML‐236A and ML‐236B, Competitive Inhibitors of 3‐Hydroxy‐3‐methylglutaryl‐Coenzyme A ReductaseEuropean Journal of Biochemistry, 1977